New PDL1 Inhibitors for Non-Small Cell Lung Cancer: Focus on Pembrolizumab

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s154606
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Pembrolizumab‐induced Secondary Sclerosing Cholangitis in a Non‐small Cell Lung Cancer Patient

Respirology Case Reports
PulmonaryRespiratory Medicine
2020English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

New Strategies in Lung Cancer: Epigenetic Therapy for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

New Developments in the Management of Non-Small-Cell Lung Cancer, Focus on Rociletinib: What Went Wrong?

OncoTargets and Therapy
OncologyPharmacology
2016English

Combination of Pembrolizumab and 125I Attenuates the Aggressiveness of Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2020English

Pembrolizumab-Induced Obstructive Bronchiolitis in a Patient With Stage IV Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2019English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy